Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

Current treatment modalities can cure up to 70–80 % of patients with classical Hodgkin lymphoma. Approximately, 20–30 % of patients require further treatment options. Brentuximab vedotin has been approved for the treatment of relapsed and refractory Hodgkin lymphoma. In the present study, we report...

Descripción completa

Detalles Bibliográficos
Autores principales: Salihoglu, A., Elverdi, T., Karadogan, I., Paydas, S., Ozdemir, E., Erdem, G., Karadurmus, N., Akyol, G., Kaynar, L., Yegin, ZA, Sucak, G., Ozkocaman, V., Topcuoglu, P., Ozcan, M., Birtas, E., Goker, H., Baslar, Z., Ferhanoglu, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317523/
https://www.ncbi.nlm.nih.gov/pubmed/25231929
http://dx.doi.org/10.1007/s00277-014-2215-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317523/
https://www.ncbi.nlm.nih.gov/pubmed/25231929
http://dx.doi.org/10.1007/s00277-014-2215-9

Ejemplares similares